Flex Pharma Stock Price, News & Analysis (NASDAQ:FLKS)

$4.16 +0.07 (+1.71 %)
(As of 02/25/2018 11:17 AM ET)
Previous Close$4.16
Today's Range$4.05 - $4.18
52-Week Range$2.68 - $5.93
Volume5,198 shs
Average Volume51,301 shs
Market Capitalization$74.76 million
P/E RatioN/A
Dividend YieldN/A
Beta3.59

About Flex Pharma (NASDAQ:FLKS)

Flex Pharma logoFlex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Receive FLKS News and Ratings via Email

Sign-up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLKS
CUSIPN/A
Phone617-874-1821

Debt

Debt-to-Equity RatioN/A
Current Ratio8.16%
Quick Ratio8.05%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.01 million
Price / Sales74.02
Cash FlowN/A
Price / CashN/A
Book Value$3.30 per share
Price / Book1.26

Profitability

Trailing EPS($2.02)
Net Income$-39,490,000.00
Net Margins-2,655.19%
Return on Equity-71.39%
Return on Assets-65.49%

Miscellaneous

Employees31
Outstanding Shares17,970,000

Flex Pharma (NASDAQ:FLKS) Frequently Asked Questions

What is Flex Pharma's stock symbol?

Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."

How were Flex Pharma's earnings last quarter?

Flex Pharma Inc (NASDAQ:FLKS) posted its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.06. The biotechnology company earned $0.41 million during the quarter, compared to analyst estimates of $0.47 million. Flex Pharma had a negative return on equity of 71.39% and a negative net margin of 2,655.19%. View Flex Pharma's Earnings History.

When will Flex Pharma make its next earnings announcement?

Flex Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Flex Pharma.

Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2018?

5 equities research analysts have issued 1-year target prices for Flex Pharma's shares. Their predictions range from $8.00 to $12.00. On average, they anticipate Flex Pharma's share price to reach $10.80 in the next year. View Analyst Ratings for Flex Pharma.

What are Wall Street analysts saying about Flex Pharma stock?

Here are some recent quotes from research analysts about Flex Pharma stock:

  • 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (2/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "Exploratory Phase II study of FLX-787 in ALS has produced statistically significant results in decreased pain intensity and stiffness (p<0.05) in a small population of 8 patients."" (11/6/2017)

Who are some of Flex Pharma's key competitors?

Who are Flex Pharma's key executives?

Flex Pharma's management team includes the folowing people:

  • Christoph H. Westphal M.D. Ph.D., Chairman of the Board (Age 48)
  • William K. McVicar Ph.D., President, Chief Executive Officer, Director (Age 59)
  • John McCabe, Chief Financial Officer, Treasurer (Age 45)
  • Kathie Lindemann, Chief Operating Officer (Age 54)
  • Jennifer Cermak Ph.D., Vice President - Research & Development (Age 42)
  • Elizabeth Woo M.D. Ph.D., Senior Vice President, Investor Relations and Corporate Communications (Age 49)
  • Thomas C. Wessel M.D. Ph.D., Chief Medical Officer (Age 60)
  • Jeffrey D. Capello, Director (Age 53)
  • Roderick Mackinnon M.D, Director (Age 59)
  • Michelle V. Stacy, Director (Age 62)

When did Flex Pharma IPO?

(FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Who owns Flex Pharma stock?

Flex Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include PRIMECAP MANAGEMENT COMPANY (10.05%), Sphera Funds Management LTD. (1.34%), Renaissance Technologies LLC (0.50%), Granite Point Capital Management L.P. (0.40%) and Millennium Management LLC (0.19%). Company insiders that own Flex Pharma stock include Christoph H Westphal, John P Mccabe, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Institutional Ownership Trends for Flex Pharma.

Who sold Flex Pharma stock? Who is selling Flex Pharma stock?

Flex Pharma's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Flex Pharma.

Who bought Flex Pharma stock? Who is buying Flex Pharma stock?

Flex Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Renaissance Technologies LLC and Granite Point Capital Management L.P.. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal, John P Mccabe, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Insider Buying and Selling for Flex Pharma.

How do I buy Flex Pharma stock?

Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flex Pharma's stock price today?

One share of Flex Pharma stock can currently be purchased for approximately $4.16.

How big of a company is Flex Pharma?

Flex Pharma has a market capitalization of $74.76 million and generates $1.01 million in revenue each year. The biotechnology company earns $-39,490,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. Flex Pharma employs 31 workers across the globe.

How can I contact Flex Pharma?

Flex Pharma's mailing address is 800 Boylston Street 24thFloor, Boston MA, 02199. The biotechnology company can be reached via phone at 617-874-1821 or via email at [email protected]


MarketBeat Community Rating for Flex Pharma (FLKS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Flex Pharma (NASDAQ:FLKS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.752.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.80$10.80$11.00$17.50
Price Target Upside: 168.66% upside168.66% upside214.29% upside435.17% upside

Flex Pharma (NASDAQ:FLKS) Consensus Price Target History

Price Target History for Flex Pharma (NASDAQ:FLKS)

Flex Pharma (NASDAQ:FLKS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2018Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$12.00HighView Rating Details
1/17/2018Cantor FitzgeraldReiterated RatingHold$10.00HighView Rating Details
1/3/2018Roth CapitalReiterated RatingBuy -> Buy$12.00LowView Rating Details
5/4/2017Jefferies GroupLower Price TargetBuy$9.00 -> $8.00HighView Rating Details
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$12.00LowView Rating Details
11/3/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/15/2016HC WainwrightReiterated RatingBuy$40.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Flex Pharma (NASDAQ:FLKS) Earnings History and Estimates Chart

Earnings by Quarter for Flex Pharma (NASDAQ:FLKS)

Flex Pharma (NASDAQ FLKS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.54)N/AView Earnings Details
11/6/2017Q3 2017($0.60)($0.54)$0.47 million$0.41 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.63)($0.51)$0.46 million$0.34 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.62)($0.49)$0.38 million$0.24 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.84)($0.48)$0.09 million$0.30 millionViewListenView Earnings Details
11/2/2016Q316($0.72)($0.65)$0.15 million$0.60 millionViewListenView Earnings Details
8/3/2016Q216($0.67)($0.71)$0.01 million$0.11 millionViewListenView Earnings Details
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details
5/6/2015Q1($0.32)($0.59)ViewListenView Earnings Details
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Flex Pharma (NASDAQ:FLKS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.33 EPS
Next Year EPS Consensus Estimate: $-2.32 EPS

Dividends

Dividend History for Flex Pharma (NASDAQ:FLKS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Flex Pharma (NASDAQ FLKS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 45.36%
Institutional Ownership Percentage: 28.32%
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)

Flex Pharma (NASDAQ FLKS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2016Christoph H WestphalInsiderBuy7,000$7.31$51,170.003,941,118View SEC Filing  
11/7/2016Christoph H WestphalInsiderBuy8,870$5.70$50,559.003,934,118View SEC Filing  
11/7/2016John P MccabeVPBuy1,650$6.01$9,916.501,650View SEC Filing  
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.003,925,248View SEC Filing  
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.003,925,248View SEC Filing  
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.003,925,248View SEC Filing  
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.003,925,248View SEC Filing  
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.003,925,248View SEC Filing  
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.003,925,248View SEC Filing  
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.003,925,248View SEC Filing  
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.003,925,248View SEC Filing  
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.003,925,248View SEC Filing  
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.003,925,248View SEC Filing  
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.003,925,248View SEC Filing  
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.003,925,248View SEC Filing  
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.283,925,248View SEC Filing  
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.843,925,248View SEC Filing  
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.003,925,248View SEC Filing  
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.253,925,248View SEC Filing  
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.043,925,248View SEC Filing  
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.463,925,248View SEC Filing  
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.783,925,248View SEC Filing  
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.923,925,248View SEC Filing  
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.003,925,248View SEC Filing  
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.173,925,248View SEC Filing  
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.552,585View SEC Filing  
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.0049,064View SEC Filing  
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.003,925,248View SEC Filing  
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00431,277View SEC Filing  
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.273,925,248View SEC Filing  
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.143,924,321View SEC Filing  
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.004,500View SEC Filing  
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.783,921,556View SEC Filing  
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.003,920,555View SEC Filing  
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.653,918,588View SEC Filing  
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.983,917,545View SEC Filing  
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.323,914,735View SEC Filing  
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Flex Pharma (NASDAQ FLKS) News Headlines

Source:
DateHeadline
$360,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter$360,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - February 23 at 2:02 AM
Zacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.85 EPSZacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.85 EPS
www.americanbankingnews.com - February 21 at 11:14 PM
Flex Pharma Inc (FLKS) Receives Consensus Rating of "Buy" from BrokeragesFlex Pharma Inc (FLKS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 19 at 1:32 AM
Zacks Investment Research Upgrades Flex Pharma (FLKS) to HoldZacks Investment Research Upgrades Flex Pharma (FLKS) to Hold
www.americanbankingnews.com - February 15 at 11:22 PM
Flex Pharma Inc to Post FY2018 Earnings of ($1.68) Per Share, Jefferies Group Forecasts (FLKS)Flex Pharma Inc to Post FY2018 Earnings of ($1.68) Per Share, Jefferies Group Forecasts (FLKS)
www.americanbankingnews.com - February 15 at 11:40 AM
Jefferies Group Comments on Flex Pharma Incs FY2022 Earnings (FLKS)Jefferies Group Comments on Flex Pharma Inc's FY2022 Earnings (FLKS)
www.americanbankingnews.com - February 14 at 4:12 PM
New Study Shows HOTSHOT™ Provides Relief From Muscle Soreness For Athletes Of All TypesNew Study Shows HOTSHOT™ Provides Relief From Muscle Soreness For Athletes Of All Types
finance.yahoo.com - February 8 at 8:29 AM
Flex Pharma Presenting at BIO CEO on February 13, 2018Flex Pharma Presenting at BIO CEO on February 13, 2018
finance.yahoo.com - February 6 at 4:00 PM
Summit Therapeutics (SMMT) vs. Flex Pharma (FLKS) Head-To-Head ContrastSummit Therapeutics (SMMT) vs. Flex Pharma (FLKS) Head-To-Head Contrast
www.americanbankingnews.com - February 6 at 1:19 PM
Flex Pharma (FLKS) Receives New Coverage from Analysts at Ladenburg Thalmann Financial ServicesFlex Pharma (FLKS) Receives New Coverage from Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - January 27 at 7:12 PM
Flex Pharma Inc (FLKS) Given Consensus Recommendation of "Buy" by BrokeragesFlex Pharma Inc (FLKS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 25 at 9:48 AM
Zacks: Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $370,000.00Zacks: Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $370,000.00
www.americanbankingnews.com - January 20 at 2:48 AM
Flex Pharma Inc (FLKS) Expected to Announce Earnings of -$0.85 Per ShareFlex Pharma Inc (FLKS) Expected to Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - January 18 at 11:28 PM
Cantor Fitzgerald Reaffirms Hold Rating for Flex Pharma (FLKS)Cantor Fitzgerald Reaffirms Hold Rating for Flex Pharma (FLKS)
www.americanbankingnews.com - January 18 at 1:50 PM
Primecap Buys More Flex Pharma, Alkermes StockPrimecap Buys More Flex Pharma, Alkermes Stock
www.msn.com - January 5 at 10:10 AM
Breaking Down Flex Pharma Inc’s (NASDAQ:FLKS) Ownership StructureBreaking Down Flex Pharma Inc’s (NASDAQ:FLKS) Ownership Structure
finance.yahoo.com - January 3 at 4:53 PM
Roth Capital Reiterates Buy Rating for Flex Pharma (FLKS)Roth Capital Reiterates Buy Rating for Flex Pharma (FLKS)
www.americanbankingnews.com - January 3 at 10:58 AM
-$0.98 EPS Expected for Flex Pharma Inc (FLKS) This Quarter-$0.98 EPS Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - January 2 at 5:26 AM
Flex Pharma (FLKS) Cut to "Hold" at Zacks Investment ResearchFlex Pharma (FLKS) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 27 at 11:38 PM
ETFs with exposure to Flex Pharma, Inc. : December 26, 2017ETFs with exposure to Flex Pharma, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 3:33 PM
What Is Flex Pharma Inc’s (NASDAQ:FLKS) Financial Position?What Is Flex Pharma Inc’s (NASDAQ:FLKS) Financial Position?
finance.yahoo.com - December 27 at 3:33 PM
Flex Pharma, Inc. :FLKS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017Flex Pharma, Inc. :FLKS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 10:10 AM
Head-To-Head Review: Flex Pharma (FLKS) & Its RivalsHead-To-Head Review: Flex Pharma (FLKS) & Its Rivals
www.americanbankingnews.com - December 21 at 7:48 AM
 Analysts Expect Flex Pharma, Inc. (FLKS) Will Post Quarterly Sales of $400,000.00 Analysts Expect Flex Pharma, Inc. (FLKS) Will Post Quarterly Sales of $400,000.00
www.americanbankingnews.com - December 18 at 10:52 AM
Flex Pharma (FLKS) vs. The Competition Head-To-Head ContrastFlex Pharma (FLKS) vs. The Competition Head-To-Head Contrast
www.americanbankingnews.com - December 9 at 1:22 AM
Should You Be Content With Flex Pharma Inc’s (FLKS) 18.4% Earnings Growth?Should You Be Content With Flex Pharma Inc’s (FLKS) 18.4% Earnings Growth?
finance.yahoo.com - December 6 at 10:19 AM
Contrasting Flex Pharma (FLKS) & Its RivalsContrasting Flex Pharma (FLKS) & Its Rivals
www.americanbankingnews.com - December 2 at 3:06 PM
Flex Pharma (FLKS) Rating Increased to Buy at Zacks Investment ResearchFlex Pharma (FLKS) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - December 1 at 9:54 PM
 Analysts Expect Flex Pharma, Inc. (FLKS) Will Post Quarterly Sales of $380,000.00 Analysts Expect Flex Pharma, Inc. (FLKS) Will Post Quarterly Sales of $380,000.00
www.americanbankingnews.com - November 30 at 12:58 PM
Enrollment Completed in Flex Pharma’s Phase 2 Exploratory Spasticity Study in MSEnrollment Completed in Flex Pharma’s Phase 2 Exploratory Spasticity Study in MS
finance.yahoo.com - November 28 at 9:04 AM
 Analysts Expect Flex Pharma, Inc. (FLKS) Will Announce Earnings of -$0.83 Per Share Analysts Expect Flex Pharma, Inc. (FLKS) Will Announce Earnings of -$0.83 Per Share
www.americanbankingnews.com - November 28 at 7:56 AM
Arnold & Havas Media, Gear Communications Awarded HOTSHOT® Creative, Media & PR DutiesArnold & Havas Media, Gear Communications Awarded HOTSHOT® Creative, Media & PR Duties
finance.yahoo.com - November 27 at 5:48 PM
Analyzing Flex Pharma (FLKS) & Urogen Pharma (URGN)Analyzing Flex Pharma (FLKS) & Urogen Pharma (URGN)
www.americanbankingnews.com - November 17 at 2:12 PM
Flex Pharma, Inc. (FLKS) Expected to Announce Quarterly Sales of $380,000.00Flex Pharma, Inc. (FLKS) Expected to Announce Quarterly Sales of $380,000.00
www.americanbankingnews.com - November 11 at 6:38 AM
Jefferies Group Analysts Boost Earnings Estimates for Flex Pharma, Inc. (FLKS)Jefferies Group Analysts Boost Earnings Estimates for Flex Pharma, Inc. (FLKS)
www.americanbankingnews.com - November 10 at 7:40 AM
 Analysts Anticipate Flex Pharma, Inc. (FLKS) to Post -$0.86 Earnings Per Share Analysts Anticipate Flex Pharma, Inc. (FLKS) to Post -$0.86 Earnings Per Share
www.americanbankingnews.com - November 9 at 3:54 PM
Flex Pharma, Inc. (FLKS) Posts  Earnings Results, Beats Expectations By $0.06 EPSFlex Pharma, Inc. (FLKS) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - November 7 at 10:08 AM
Flex Pharma, Inc. to Host Earnings CallFlex Pharma, Inc. to Host Earnings Call
finance.yahoo.com - November 6 at 10:38 PM
Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALSFlex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS
finance.yahoo.com - November 6 at 10:38 PM
Flex Pharma Reports Third Quarter 2017 Financial ResultsFlex Pharma Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 10:38 PM
Flex Pharma reports 3Q lossFlex Pharma reports 3Q loss
finance.yahoo.com - November 6 at 10:38 PM
Edited Transcript of FLKS earnings conference call or presentation 6-Nov-17 1:45pm GMTEdited Transcript of FLKS earnings conference call or presentation 6-Nov-17 1:45pm GMT
finance.yahoo.com - November 6 at 10:38 PM
Cantor Fitzgerald Reaffirms Hold Rating for Flex Pharma, Inc. (FLKS)Cantor Fitzgerald Reaffirms Hold Rating for Flex Pharma, Inc. (FLKS)
www.americanbankingnews.com - November 6 at 4:18 PM
Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017
finance.yahoo.com - November 2 at 8:00 PM
Flex Pharma Names Dr. Roger Tung to Its Board of DirectorsFlex Pharma Names Dr. Roger Tung to Its Board of Directors
finance.yahoo.com - October 31 at 7:56 PM
Should You Buy Flex Pharma Inc (FLKS) Now?Should You Buy Flex Pharma Inc (FLKS) Now?
finance.yahoo.com - October 31 at 7:56 PM
Flex Pharma, Inc. (FLKS) Scheduled to Post Earnings on TuesdayFlex Pharma, Inc. (FLKS) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 24 at 5:46 AM
$470,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter$470,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - October 22 at 5:04 AM
Flex Pharma (FLKS) and Kitov Pharmaceuticals Holdings (KTOV) Head to Head ContrastFlex Pharma (FLKS) and Kitov Pharmaceuticals Holdings (KTOV) Head to Head Contrast
www.americanbankingnews.com - October 21 at 4:24 AM
Flex Pharma, Inc. (FLKS) Expected to Post Earnings of -$0.62 Per ShareFlex Pharma, Inc. (FLKS) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - October 20 at 8:28 PM

SEC Filings

Flex Pharma (NASDAQ:FLKS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Flex Pharma (NASDAQ:FLKS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Flex Pharma (NASDAQ FLKS) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.